


SECTION 1: PRODUCT IDENTIFICATION

PRODUCT NAME	CHLORPROMAZINE HYDROCHLORIDE, USP
PRODUCT CODE	0423
SUPPLIER	MEDISCA Inc. Tel.: 1.800.932.1039 Fax.: 1.855.850.5855 661 Route 3, Unit C, Plattsburgh, NY, 12901 6641 N. Belt Line Road, Suite 130, Irving, TX, 75063 MEDISCA Pharmaceutiqe Inc. Tel.: 1.800.665.6334 Fax.: 514.338.1693 4509 Rue Dobrin, St. Laurent, QC, H4R 2L8 21300 Gordon Way, Unit 153/158, Richmond, BC V6W 1M2 MEDISCA Australia PTY LTD Tel.: 1.300.786.392 Fax.: 61.2.9700.9047 Unit 7, Heritage Business Park 5-9 Ricketty Street, Mascot, NSW 2020
EMERGENCY PHONE	CHEMTREC Day or Night Within USA and Canada: 1-800-424-9300 NSW Poisons Information Centre: 131 126 National Chemical Emergency Centre 44(0)1235239670
RECOMMENDED USES	Manufacturing and Compounding
RESTRICTIONS ON USE	Not applicable

SECTION 2: HAZARDS IDENTIFICATION

GHS CLASSIFICATION	Acute Toxicity - Oral (Category 3) Acute Toxicity - Inhalation (Category 4) Eye Irritation (Category 2A) Sensitization - Skin (Category 1) Specific Target Organ Toxicity - Single Exposure (Category 1) - (Heart) Specific Target Organ Toxicity - Repeated Exposure (Category 1) - (Nervous system) Chronic Aquatic Toxicity (Category 1)
PICTOGRAM	
SIGNAL WORD	Danger
HAZARD STATEMENT(S)	Toxic if swallowed. Harmful if inhaled. Causes serious eye irritation. Suspected of damaging fertility or the unborn child. Suspected of causing cancer. May cause an allergic skin reaction. May cause drowsiness or dizziness. Causes damage to organs. Causes damage to organs through prolonged or repeated exposure. Very toxic to aquatic life with long lasting effects.

ADVERSE PHYSIOCHEMICAL, HUMAN HEALTH AND ENVIRONMENTAL EFFECTS

Not Applicable.

PRECAUTIONARY STATEMENT(S)
Prevention

Wear eye and face protection.
 Wear protective gloves.
 Wash hands thoroughly after handling. Do not touch eyes.
 Contaminated work clothing must not be allowed out of the workplace.
 In case of inadequate ventilation wear respiratory protection.
 Use only outdoors or in a well-ventilated area.
 Do not breathe dust/fume/gas/mist/vapors/spray.
 Do not eat, drink or smoke when using this product.
 Avoid release to the environment

Response

IF SWALLOWED: Immediately call a poison center. Get emergency medical help immediately. Rinse mouth.
 IF ON SKIN: Wash with plenty of water. If skin irritation or rash occurs: Get medical help advice/attention. Take off contaminated clothing and wash it before reuse.
 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Get medical help.
 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists, get medical help.
 IF EXPOSED: Get emergency medical help immediately. Call a poison center or doctor.
 COLLECT SPILLAGE
 Get medical help if you feel unwell.

Storage

Store locked up.

Disposal

Dispose of contents and/or container in accordance with local regulations.

HMIS CLASSIFICATION
Health Hazard

3

Flammability

0

Reactivity

0

Personal Protection

G

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS
CHEMICAL NAME

2-Chloro-10-[3-(dimethylamino) propyl] phenothiazine monohydrochloride.

BOTANICAL NAME

Not applicable

SYNONYM

Not applicable

CHEMICAL FORMULA
 $C_{17}H_{19}ClN_2S \cdot HCl$
CHEMICAL FAMILY

Phenothiazine

CAS NUMBER

69-09-0

ALTERNATE CAS NUMBER

Not applicable

MOLECULAR WEIGHT

355.331

COMPOSITION

CHEMICAL NAME	CAS NUMBER	EC NUMBER	% BY WEIGHT
CHLORPROMAZINE HCl	69-09-0	200-701-3	100

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as health hazards and hence require reporting in this section.

SECTION 4: FIRST-AID MEASURES
IN CASE OF EYE CONTACT

Flush with copious amounts of water for 15 minutes, separating eyelids with fingers. If irritation persists seek medical aid.

IN CASE OF SKIN CONTACT

Wash with soap & water for 15 minutes. If irritation persists seek medical aid.

IF SWALLOWED

Call a physician. Wash out mouth with water. Do not induce vomiting without medical advice.

IF INHALED

Remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Call a physician

MEDICAL ATTENTION AND SPECIAL TREATMENT

Get emergency medical help.

SYMPTOMS CAUSED BY EXPOSURE

Not expected to present a significant hazard under anticipated conditions of normal use.

SECTION 5: FIREFIGHTING MEASURES

SPECIFIC HAZARDS ARISING FROM THE CHEMICAL

Not applicable.

FLAMMABLE PROPERTIES

Combustible dust.

HAZARDOUS COMBUSTION PRODUCTS

Under fire conditions, hazardous fumes will be present.

SUITABLE & UNSUITABLE EXTINGUISHING MEDIA

Small fire: dry chemical, CO₂ or water spray. **Large fire:** dry chemical, CO₂, alcohol resistant foam or water spray. Do not get water inside containers.

PROTECTIVE EQUIPMENT AND PRECAUTIONS FOR FIREFIGHTERS

Wear self-contained breathing apparatus and protective clothing to prevent contact with skin and eyes.

NOTES

Potential for dust explosion: Weak dust explosion potential.

Dust explosion properties:

Kst: 192 bar.m/s

Minimum ignition energy (MIE) - dust cloud: 1 - 3 mJ

SECTION 6: ACCIDENTAL RELEASE MEASURES

PERSONAL PRECAUTIONS

Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.

METHODS & MATERIAL FOR CONTAINMENT

On land, sweep or shovel into suitable containers. Minimize generation of dust.

CLEANUP PROCEDURE

Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Wear respirator, chemical safety goggles, rubber boots and heavy rubber gloves. Stop leak if you can do it without risk. Prevent entry into waterways, sewers, basements or confined areas. Shut off all sources of ignition. Evacuate the area. If necessary, employ water fog to disperse the vapors. Absorb the matter with compatible vermiculite or other absorbing material. Place in a suitable container and retain for disposal. Ventilate and clean the affected area. Do not flush into sewerage system or to drains.

REFERENCE TO OTHER SECTIONS

See Section 7 for information on safe handling. See Section 8 for information on personal protection equipment. See Section 13 for disposal information.

SECTION 7: HANDLING AND STORAGE

PRECAUTIONS FOR SAFE HANDLING

Do not inhale. Avoid contact with eyes, skin and clothing. Avoid prolonged or repeated exposure. Wash thoroughly after handling. Store away from incompatible materials, in a well-ventilated area. Eliminate all sources of ignition. Store in accordance with local regulations. Do not store in unlabeled containers. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Use appropriate containment to avoid environmental contamination.

CONDITIONS FOR SAFE STORAGE

Store away from incompatible materials, in a well-ventilated area. Eliminate all sources of ignition. Store in accordance with local regulations. Do not store in unlabeled containers. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Use appropriate containment to avoid environmental contamination.

STORAGE CONDITIONS

Store in original container, tightly sealed, protected from direct sunlight and moisture.

Short term excursions, temperature excursions as experienced during shipping and warehousing, up to 40°C are acceptable.

SECTION 8: EXPOSURE CONTROLS/ PERSONAL PROTECTION

Chemical Name: CHLORPROMAZINE HCl CAS #: 69-09-0

	Country	Limit value-8 hours		Limit value-Short Term		IDLH	REL	Advisory	Notes
		ppm	mg/m ³	ppm	mg/m ³				
OSHA	USA	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
ACGIH	USA	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
NIOSH	USA	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
WEEL	USA	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
HSIS	Australia	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
HSE	UK	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
GESTIS	Add Country	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A

N/L = Not listed ; N/A = Not Available

PELs are 8-hour TWAs = Limit value - Eight hours

Ceiling or Short-Term TWA = STEL = Limit value - Short term

EXPOSURE GUIDELINES

Consult local authorities for provincial or state exposure limits. Particulates not otherwise regulated, respirable fraction: 5 mg/m³

PERSONAL PROTECTIVE EQUIPMENT

Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by WHMIS or OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166. **Skin:** Wear appropriate gloves to prevent skin exposure. **Clothing:** Wear appropriate protective clothing to minimize contact with skin. **Respirators:** Follow WHMIS or OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced. **Thermal Hazards:** For products representing a thermal hazard, appropriate Personal Protective Equipment should be used.

SPECIFIC ENGINEERING CONTROLS

Adequate mechanical ventilation. Fumehood, eye wash station, and safety shower.

BIOLOGICAL MONITORING

Not available

CONTROL BANDING

Not available

NOTES

USP: ELV: Industrial use: TWA: 15 micrograms/m³

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES
PHYSICAL STATE

Solid

DESCRIPTION

White or slightly creamy white, odorless, crystalline powder. Darkens on exposure to light.

SOLUBILITY

Very soluble in water; freely soluble in alcohol and in chloroform; insoluble in ether and in benzene.

ODOR

Odorless

FLAMMABILITY

Combustible dust

AUTO-IGNITION TEMPERATURE	430°C, 806°F	BOILING POINT	Not available	DECOMPOSITION TEMPERATURE	Not available
EVAPORATION RATE	Not available	EXPLOSIVE LIMIT	Not available	FLASH POINT	Not available
log P (OCTANOL-WATER)	5.35	LOWER FLAMMABLE/EXPLOSIVE LIMIT(S)	Not available	MELTING/FREEZING POINT	(195-198)°C, (383-388.4)°F
PARTICLE CHARACTERISTICS	Not available	OXIDIZING PROPERTY	Not available	pH	3.5 - 4.5 (10%)
RELATIVE DENSITY (WATER = 1)	Not available	SPECIFIC GRAVITY	Not available	UPPER FLAMMABLE/EXPLOSIVE LIMIT(S)	Not available
VAPOR DENSITY (AIR = 1)	Not available	VAPOR PRESSURE	Not available	VISCOSITY	Not available

The physical data presented above are typical values and should not be construed as a specification.

SECTION 10: STABILITY AND REACTIVITY

REACTIVITY	Not established
CHEMICAL STABILITY	Stable under recommended storage conditions
INCOMPATIBLE MATERIALS	Strong oxidants
HAZARDOUS DECOMPOSITION PRODUCTS	Toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides and other gases may occur
HAZARDOUS POLYMERIZATION	Will not occur
POSSIBILITY OF HAZARDOUS REACTION	Not established
CONDITIONS TO AVOID	Moisture, sunlight and extreme temperatures

SECTION 11: TOXICOLOGICAL INFORMATION

ACUTE TOXICITY	Oral: Rat: LD50: (mg/kg): 145 Dermal: Rabbit LD50: (mg/kg): Not available Inhalation: Rat: LC50: (mg/L/4hr): 1.33
SKIN CORROSION/IRRITATION	Due to lack of data the classification is not possible.
SERIOUS EYE DAMAGE/EYE IRRITATION	Causes serious eye irritation.
RESPIRATORY SENSITIZATION	Due to lack of data the classification is not possible.
SKIN SENSITIZATION	May cause an allergic skin reaction. Hypersensitivity reactions include urticaria, exfoliative dermatitis, erythema multiforme, and contact sensitivity.
GERM CELL MUTAGENICITY	Based on available data, the classification criteria are not met. Suspected mutagen: equivocal mutagenicity data according to ISSSTY

CARCINOGENICITY
OSHA CHLORPROMAZINE HCl is not listed.

NTP CHLORPROMAZINE HCl is not listed.

IARC CHLORPROMAZINE HCl is not evaluated.

California Proposition 65 This product does not contain any chemicals known to the State of California to cause cancer, birth defects, or any other reproductive harm.

ADDITIONAL CARCINOGENICITY INFORMATION

Based on available data, the classification criteria are not met.

Suspected carcinogen: The Toolbox profiler Carcinogenicity (genotox and nongenotox) alerts by ISS gives an alert for carcinogenicity.

Phenothiazines produce an elevation in prolactin concentrations. In vitro studies show about 1/3 of human breast cancers are prolactin-dependent. Studies in rodents found an increase in mammary tumors after long-term administration of antipsychotic medications. Early epidemiological studies did not show an association between chronic administration of antipsychotics and breast cancer in women. A later study found a modest dose-related increased risk of breast cancer in women using antipsychotic dopamine antagonists. The available evidence is inconclusive.

2.5 - 10 mg/kg Carcinogenicity study. Result: Negative. Species: Mouse.

REPRODUCTIVE TOXICITY

Based on available data, the classification criteria are not met.

Suspected of damaging the unborn child. Suspected of damaging fertility.

Long term treatment has been shown to increase the incidence of mammary tumors in rat.

Suspected toxic for reproduction: The Toolbox profiler DART scheme v.1.0 gives an alert for toxicity to reproduction; CAESAR developmental toxicity model in VEGA (Q)SAR platform predicts that the chemical is Toxicant (good reliability); Developmental/Reproductive Toxicity library (PG) in VEGA (Q)SAR platform predicts that the chemical is Toxicant (moderate reliability); DART database in the Toolbox reports that this substance as Known developmental potential.

There have been reports of prolonged jaundice, under or overactive reflexes, movement disorders, and withdrawal effects (runny nose, vomiting, difficulty breathing) in newborns exposed to phenothiazines in utero. Altered behavior and neurological function was seen in offspring of rodents treated with this material during pregnancy. Epidemiological studies have not shown an association between therapeutic use of this material during pregnancy and an increased incidence of birth defects.

0 - 30 mg/kg/day Reproductivity and development study. Result: Not teratogenic; increased prenatal mortality. Species: Rat.

0.6 mg/kg Reproductivity and development study; Result: Embryotoxicity; Species: Rat

10 mg/kg Reproductivity and development study. Result: Fetotoxicity; no increased incidence of birth defects.

Species: Rat

16 mg/kg Reproductivity and development study. Result: Maternal toxicity; fetotoxicity. Species: Mouse

SPECIFIC TARGET ORGAN TOXICITY - SINGLE EXPOSURE

Causes damage to organs (heart). Has sedative effects.

SPECIFIC TARGET ORGAN TOXICITY - REPEATED EXPOSURE

Causes damage to organs (nervous system) through prolonged or repeated exposure.

ASPIRATION HAZARDS

Based on available data, the classification criteria are not met.

SIGNS AND SYMPTOMS OF EXPOSURE
ROUTES OF EXPOSURE:

Oral, Dermal, Inhalation, Eye contact

EARLY ONSET SYMPTOMS RELATED TO EXPOSURE:

Not available

DELAYED HEALTH EFFECT FROM EXPOSURE:

Blood disorders. Phenothiazines: Coma. Extrapyramidal effects. Low blood pressure. Hypothermia or hyperthermia. Central nervous system toxicity. Cardiac toxicity. Respiratory depression. Sudden death.

For phenothiazines: Abnormal heartbeat. Sudden death. Involuntary movement (muscle spasms; uncontrolled body movements; difficulty breathing, speaking, or swallowing; loss of balance; trembling or shaking hands and fingers; shuffling walk; unusual facial expressions; eyelid spasms; twisting of neck, trunk, arms, or legs). Rigidity. Weakness. Incoordination. Dizziness. Drowsiness. Disorientation. Pinpoint pupils. Yellow eyes and/or skin. Dry mouth. Constipation. Nasal congestion. Decreased sweating. Difficulty urinating. Increased sensitivity of skin or eyes to sunlight. Skin rash. Skin discoloration. Changes in menstrual period. Swelling or pain in breasts or milk secretion. Weight gain. Vomiting. Convulsions. Coma.

Chronic effects:

For phenothiazines: Skin and eye discoloration. Tardive dyskinesia.

Cross sensitivity:

Persons sensitive to one phenothiazine may be sensitive to this material also.

Medical conditions aggravated by exposure:

Phenothiazines: Active alcoholism. Blood, liver, kidney, respiratory, or cardiovascular disorders. Pheochromocytoma. History of convulsive disorders, brain damage, neuroleptic malignant syndrome, or dermatoses. Acquired immune deficiency syndrome (AIDS). Glaucoma. Parkinson's disease. Reye's syndrome. Breast cancer. Hypocalcemia. Exposure to extreme heat or phosphorus insecticides.

POTENTIAL HEALTH EFFECTS

Inhalation	Harmful if inhaled. Causes respiratory tract irritation.
Ingestion	Toxic if swallowed.
Skin	May be harmful if absorbed through skin. Causes skin irritation. May cause an allergic skin reaction.
Eyes	Causes serious eye irritation.

SECTION 12: ECOLOGICAL INFORMATION

ECOTOXICITY

EC50: 48 Hr: Crustacea: (mg/L): Not available
 LC50: 96 Hr: Fish: (mg/L): Not available
 EC50: 96Hr: Algae: (mg/L): <1*

PERSISTENCE AND DEGRADABILITY

Suspected persistent in the environment: The Danish QSAR database contains information indicating that the substance is predicted as non readily biodegradable.

BIOACCUMULATIVE POTENTIAL

High: LogPow: 5.35

MOBILITY IN SOIL

Solubility in water: 400 g/L (Very soluble)

OTHER ADVERSE EFFECTS

Not available

This product is not intended to be released into the environment

NOTES

*Danish QSAR database

SECTION 13: DISPOSAL CONSIDERATIONS

DISPOSAL METHODS

Dispose of in accordance with federal / local laws and regulations. Avoid release into the environment.

SECTION 14: TRANSPORT INFORMATION

UN PROPER SHIPPING NAME	TOXIC SOLID, ORGANIC, N.O.S.
UN NUMBER	2811
CLASS	6.1
PACKING GROUP	III
AUSTRALIA	
HAZCHEM	2X
EU	
TRANSPORT IN BULK ACCORDING TO ANNEX II OF MARPOL 73/78 AND THE IBC CODE	Not Listed
ENVIRONMENTAL HAZARDS	Not available
SPECIAL SHIPPING INFORMATION	Not applicable

SECTION 15: REGULATORY INFORMATION
UNITED STATES REGULATIONS

Chemical Name & CAS	CERCLA 40 CFR Part 302.4	SARA (Title III) 40 CFR Part 372.65	EPA 40 CFR Part 355		Pennsylvania	Right-to-know		California Prop 65
			Appendix A	Appendix B		New Jersey	Massachusetts	
CHLORPROMAZINE HCl, 69-09-0	N/L	N/L	N/L	N/L	N/L	N/L	N/L	N/L

N/L = Not Listed; X = Listed

AUSTRALIAN REGULATIONS

Chemical Name & CAS	Poisons and Therapeutic Goods	Therapeutic Goods Act	Code of Practices - Illicit Drug Precursors	Poisons Standard	Work Health and Safety Regulations	Inventory of Industrial Chemicals
CHLORPROMAZINE HCl, 69-09-0	N/L	Listed as Schedule 4*	N/L	Listed*	N/L	N/L

N/L = Not Listed

EU REGULATIONS

Chemical Name & CAS	REACH ANNEX XVII	REACH ANNEX XIV	EC 1005/2009	EC 850/2004	EC 1107/2009	PIC - Prior Informed Consent Regulation	EC 2012/18
CHLORPROMAZINE HCl, 69-09-0	N/L	N/L	N/L	N/L	N/L	N/L	N/L

N/L = Not Listed; X = Listed

Any EU regulation not listed above is not applicable to this product.

SUBJECT TO INTERNATIONAL AGREEMENT Not applicable

NOTES

*Listed as the base

SECTION 16: OTHER INFORMATION

REFERENCES

Available upon request

ABBREVIATIONS AND ACRONYMS

ACGIH - American Conference of Governmental Industrial Hygienists; **AIHA WEEL** – American Industrial Hygiene Association Workplace Environment Exposure Levels; **CAESAR** – Computer Assisted Evaluation of industrial chemical Substances According to Regulations; **CAS** – Chemical Abstract Service; **CERCLA** – Comprehensive Environmental Response, Compensation, and Liability Act; **EC50** – Effective Concentration, 50%; **EPA** – Environmental Protection Agency; **GHS** – Global Harmonized System; **HMIS** – Hazardous Materials Information System; **HSE** – Health and Safety Executive; **HSIS** – Hazardous Substances Information System; **IARC** – International Agency for Research on Cancer; **IDLH** - Immediately Dangerous to Life or Health; **IRFMN** – Ready Biodegradability Model; **ISS** – Istituto Superiore Sanità; **LC50** – Lethal Concentration, 50%; **LD50** – Lethal Dose, 50%; **MSHA** - Mine Safety and Health Administration; **NIOSH** – National Institute for Occupational Safety and Health; **NTP** – National Toxicology Program; **OSHA PEL** – Occupational Safety & Health Administration Permissible Exposure Limits; **QSAR** – Quantitative Structure-activity relationship; **REL** - Recommended Exposure Limit; **SARA** – Superfund Amendments and Reauthorization Act; **STEL** – Short Term Exposure Limit; **TLV** – Threshold Limit Value; **TWA** – Time Weighted Average; **WHMIS** – Workplace Hazardous Materials Information System

LAST REVISION

02/2023

SUPERSEDES

04/2021

For a list of changes to the SDS since the last version, please communicate with MEDISCA at www.medisca.com

DISCLAIMER

This document was created in accordance with OSHA, Safe Work Australia and WHMIS regulations. The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. MEDISCA® shall not be held liable for any damage resulting from handling or from contact with the above product. Recipients of the product must take responsibility for observing existing laws and regulations.

SUPPLEMENTARY INFORMATION

For all country specific requirements not outlined on this Safety Data Sheet, please request Supplementary Page to this Safety Data Sheet.